Industry News
New Target Plus New Drug Equals Death Of Melanoma Cells
Apr 11, 2013
Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research (AACR) Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer surv... Read More
Genes Related To The Regulation Of The Cell Cycle Are Associated With Poor Patient Outcomes In Lung And Bladder Cancers
Apr 11, 2013
Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes... Read More
Combination Of 2 Existing Drugs Appears Safe In Patients Who Have Not Responded To Previous Treatments For Resistant Lung Cancer
Apr 11, 2013
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013... Read More
Space Radiation Reduces Ability Of Intestinal Cells To Destroy Oncoprotein, May Increase Colorectal Cancer Risk
Apr 11, 2013
Two studies funded by NASA and presented at the AACR Annual Meeting 2013 help explain why space radiation may increase the risk of colorectal cancer in humans... Read More
Tool Could Help Discover New Compounds, Combinations; Quickly Identify Most Effective Gastrointestinal Stromal Tumor Treatments
Apr 11, 2013
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013... Read More
Study Identifies A Protein That Helps Trigger Both Normal Fetal Growth And Cancer
Apr 11, 2013
Two researchers at the National Institutes of Health discovered a new genetic link between the rapid growth of healthy fetuses and the uncontrolled cell division in cancer. The findings shed light on normal development and on the genetic underpinnings of common cancers. The work, conducted using mouse and human tissue, appears in the Proceedings of the National Academy of Sciences... Read More
Hereditary Neuropathy And Chemotherapy-Induced Peripheral Neuropathy May Share Genetic Roots In Some Patients
Apr 11, 2013
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy, a condition that is hard to predict and often debilitating enough to cause cancer patients to stop their treatment early... Read More
Neuroblastomas Vulnerable To Novel Class Of Drugs May Be Identified By Genetic Biomarker
Apr 11, 2013
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists reported at the annual meeting of the American Association for Cancer Research in Washington, April 6-10... Read More
In Pediatric Bone Cancer, K9 Osteosarcoma Samples Identify Drivers Of Metastasis
Apr 11, 2013
Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year... Read More
Promising Phase I Clinical Trial Of Rogosertib Leads To Multi-Institutional Phase II Trial
Apr 11, 2013
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors... Read More
Previous Page Next Page